# Proteins: Key Drug Targets in the Treatment of Cancer

Proteins play a major role in cellular processes. Their widespread presence and versatility make them key targets for pharmaceutical action against a variety of diseases, especially cancer. The reason an emphasis is placed on the proteins is that many diseases arise due to dysregulation of protein activities and also because protein functions can easily be altered by low molecular weight drugs or bioactive agents (The National Cancer Institute, 2024; Kumar et al., 2021).

## The Cancer-Protein Relationship

Cancer often emanates as a result of genetic mutation that leads to a disruption in the normal expression, structure, or function of proteins. Several therapies target these aberrant proteins so as to address the molecular underpinning of cancer with minimal toxicity to healthy cells (Hu et al., 2021; Jin et al., 2019). Examples of therapies targeting these aberrant proteins have pointed to a number of key classes of proteins that represent potential targets:

1. **Kinases**-are enzymes involved in cell signaling and their activity is considerably higher in cancerous cells than in normal cells. An example includes imatinib, commercially known as Gleevec, which works by targeting the BCR-ABL fusion protein in chronic myeloid leukemia and successfully inhibits the leukemic cells from uncontrollable proliferation (Ventura et al., 2006).

2. **Growth Factor Receptors**-These proteins are highly expressed in cancers, and the most targeted one is Epidermal Growth Factor Receptor (EGFR). The drugs include erlotinib among others; they target these receptors to slow growth for such tumors (Li et al., 2023; Zubair & Bandyopadhyay, 2023).

3. **Apoptosis Regulators**: These are proteins, including BCL-2, that prevent programmed cell death. Drugs such as venetoclax induce the death of cancer cells by inhibiting these proteins (Ventura et al., 2006).

4. **DNA Repair Proteins**: These are targeted by a class of drugs known as PARP inhibitors, which exploit a weakness in some cancer cells to initiate cell death (Richard et al., 2022; Bellio et al., 2019; Zheng et al., 2024).

5. **Immune Checkpoint Proteins**: Drugs targeted against the proteins PD-1 and CTLA-4 have played major roles in introducing cancer immunotherapy into clinical practice as a means of modulating anti-tumor T-cell responses (Wang et al., 2022; Zhang et al., 2021).

## From Target Identification to Drug Development

The exploitation of proteins as drug targets is done in several ways:

1. **Target Identification**: With the help of techniques related to genomics and proteomics, numerous proteins are identified as being differentially expressed or mutated in cancer cells (Schenone et al., 2013; Tabana et al., 2023).

2. **Target Validation**: Application of other technologies like gene knockdown or overexpression studies confirms the exact contribution of the identified protein in cancer biology (Hughes et al., 2011).

3. **Drug Development**: Efforts put into the development of small molecules or antibodies that have the ability to effectively bind to and modulate the target protein once validated (The National Cancer Institute, 2024).

## Challenges and Future Directions

Despite the high promise entailed by therapies targeted at proteins, there are challenges. Some potentially critical targets are known to be "undruggable" because they lack suitable binding sites. Moreover, cancer cells might develop resistance to certain targeted therapies by mutating the target protein or activating substitute pathways (Shen et al., 2018; Dale et al., 2021).

However, recent advances are expanding the horizons of protein-targeting drug discovery by:

i) **Structural Biology Advances**: Techniques such as cryoelectron microscopy, together with computational methods like AlphaFold, have provided unprecedented insight into protein structure, enabling much more precise design of drugs (Callaway et al., 2020; Díaz-Holguín et al., 2024).

ii) **Novel Approaches**: New strategies, which include the use of Proteolysis Targeting Chimeras, or PROTACs, to expand the range of druggable proteins to previously unreachable targets (Sun et al., 2019; Riching et al., 2019).

## Conclusion

Proteins remain at the forefront of cancer drug discovery, driving the development of more precise and effective therapies. By focusing on these molecular drivers of cancer, researchers are moving closer to the goal of personalized cancer medicine, where treatments can be tailored to the specific protein aberrations in each patient's tumor.

## References

1. Kumar, S., Goel, D., Neeraj, & Maurya, V.K. (2021). Proteins Involved in Colorectal Cancer: Identification Strategies and Possible Roles. In: Nagaraju, G.P., Shukla, D., & Vishvakarma, N.K. (eds) Colon Cancer Diagnosis and Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-63369-1_9
2. The National Cancer Institute. (n.d.). Targeted Therapy for Cancer. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies Accessed: 2024-09-04
3. Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., ... & Chen, M. (2021). Targeting mutant p53 for cancer therapy: direct and indirect strategies. Journal of hematology & oncology, 14, 1-19.
4. Jin, J., Wu, X., Yin, J., Li, M., Shen, J., Li, J., ... & Qu, L. (2019). Identification of genetic mutations in cancer: challenge and opportunity in the new era of targeted therapy. Frontiers in oncology, 9, 263.
5. Ventura, J. J., & Nebreda, Á. R. (2006). Protein kinases and phosphatases as therapeutic targets in cancer. Clinical and Translational Oncology, 8(3), 153-160.
6. Li, Y., Mao, T., Wang, J., Zheng, H., Hu, Z., Cao, P., ... & Lin, F. (2023). Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. Cell Communication and Signaling, 21(1), 71.
7. Zubair, T., & Bandyopadhyay, D. (2023). Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities. International Journal of Molecular Sciences, 24(3), 2651.
8. Richard, I. A., Burgess, J. T., O'Byrne, K. J., & Bolderson, E. (2022). Beyond PARP1: the potential of other members of the poly (ADP-Ribose) polymerase family in DNA repair and cancer therapeutics. Frontiers in Cell and Developmental Biology, 9, 801200.
9. Bellio, C., DiGloria, C., Foster, R., James, K., Konstantinopoulos, P. A., Growdon, W. B., & Rueda, B. R. (2019). PARP inhibition induces enrichment of DNA repair–proficient CD133 and CD117 positive ovarian cancer stem cells. Molecular Cancer Research, 17(2), 431-445.
10. Zheng, L. L., Wang, L. T., Pang, Y. W., Sun, L. P., & Shi, L. (2024). Recent advances in the development of deubiquitinases inhibitors as antitumor agents. European Journal of Medicinal Chemistry, 116161.
11. Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., ... & Cheng, Q. (2022). Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. Journal of Hematology & Oncology, 15(1), 111.
12. Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., ... & Cheng, Q. (2021). Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research, 40(1), 184.
13. Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013). Target identification and mechanism of action in chemical biology and drug discovery. Nature chemical biology, 9(4), 232-240.
14. Tabana, Y., Babu, D., Fahlman, R., Siraki, A. G., & Barakat, K. (2023). Target identification of small molecules: an overview of the current applications in drug discovery. BMC biotechnology, 23(1), 44.
15. Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British journal of pharmacology, 162(6), 1239-1249.
16. Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., ... & Peng, G. (2018). ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature medicine, 24(5), 556-562.
17. Dale, B., Cheng, M., Park, K. S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021). Advancing targeted protein degradation for cancer therapy. Nature Reviews Cancer, 21(10), 638-654.
18. Callaway, E. (2020). Revolutionary cryo-EM is taking over structural biology. Nature, 578(7794), 201-202.
19. Díaz-Holguín, A., Saarinen, M., Vo, D. D., Sturchio, A., Branzell, N., Cabeza de Vaca, I., ... & Svenningsson, P. (2024). AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine–associated receptor 1. Science Advances, 10(32), eadn1524.
20. Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., ... & Rao, Y. (2019). PROTACs: great opportunities for academia and industry. Signal transduction and targeted therapy, 4(1), 64.
21. Riching, K. M., Mahan, S., Corona, C. R., McDougall, M., Vasta, J. D., Robers, M. B., ... & Daniels, D. L. (2018). Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action. ACS chemical biology, 13(9), 2758-2770.
